西班牙输血依赖性较低风险骨髓增生异常综合征的发病率、治疗模式及预后研究
基于BIG-PAC®数据库的西班牙输血依赖性较低风险骨髓增生异常综合征发病率、一线治疗模式及临床结局的观察性回顾性研究
The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain
研究概览
地位
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
-
Madrid、西班牙、28001
- Local Institution - 0001
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population will consist of adult participants diagnosed with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) identified in Spain using the BIG-PAC® database
描述
Inclusion Criteria:
- Age ≥18 years at the time of lower-risk myelodysplastic syndromes (LR-MDS) diagnosis.
- Documented diagnosis of LR-MDS identified through International Classification of Diseases (ICD) 9 codes recorded in medical history. In addition, recorded diagnosis of MDS with an explicitly documented International Prognostic Scoring System (IPSS) category of low or intermediate-1 and/or revised IPSS category of very low or low at or around the index date.
- Evidence of transfusion dependence, defined as receiving ≥2 red blood cell (RBC) units within an 8-week interval, occurring within the selection window (January 1, 2021, to May 31, 2025, or the latest date ensuring detectable follow-up).
- Active participants in BIG-PAC®, defined as ≥1 claim of any kind within 12 months prior to or on the index date (baseline period).
- A minimum of 6 months of follow-up data available after the index date, unless the patient dies earlier
Exclusion Criteria:
- Diagnosis of high-risk MDS (HR-MDS) or another hematologic malignancy (e.g., acute myeloid leukemia) before the index date.
- Documented transformation to acute myeloid leukemia (AML) or HR-MDS occurring before initiation of first-line treatment.
- Participation in interventional clinical trials during the period of first-line treatment.
- Presence of anemia secondary to non-MDS-related causes, such as nutritional deficiencies, advanced chronic kidney disease, or active bleeding, when such conditions preclude accurate attribution of transfusion dependence to MDS.
- Lack of sufficient clinical history, defined as <12 months of observable data before the index date.
- Have missing key variables, e.g., age or sex.
- Incomplete or inconsistent clinical information that prevents reliable evaluation of key study variables, including transfusion dependence status, treatment patterns, or outcomes.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Cohort 1
Overall cohort of participants with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) |
According to the product label According to the product label According to the product label According to the product label According to the product label |
|
Cohort 2
Participants that initiated first-line treatment with erythropoiesis-stimulating agents (ESAs) |
According to the product label |
|
Cohort 3
Participants that initiated first-line treatment with luspatercept |
According to the product label |
|
Cohort 4
Participants that initiated first-line treatment with hypomethylating agents (HMAs) |
According to the product label |
|
Cohort 5
Participants that initiated first-line treatment with lenalidomide |
According to the product label |
|
Cohort 6
Participants that receive conservative management (red blood cell transfusions without disease modifying therapy) |
According to the product label |
|
Cohort 7
Participants with low red-blood cell (RBC) transfusion dependance (<4 RBC per 8 weeks) |
According to the product label |
|
Cohort 8
Participants with moderate red-blood cell (RBC) transfusion dependance (4-5 RBC per 8 weeks) |
According to the product label |
|
Cohort 9
Participants with high red-blood cell (RBC) transfusion dependance (≥6 RBC per 8 weeks) |
According to the product label |
|
Cohort 10
Participants aged <75 years |
According to the product label According to the product label According to the product label According to the product label According to the product label |
|
Cohort 11
Participants aged ≥75 years |
According to the product label According to the product label According to the product label According to the product label According to the product label |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
输血依赖性较低风险骨髓增生异常综合征(TD LR-MDS)的发生率
大体时间:长达5年
|
长达5年
|
|
输血依赖性低风险骨髓增生异常综合征(TD LR-MDS)的患病率
大体时间:长达5年
|
长达5年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
合并症数量
大体时间:基线
|
基线
|
|
|
参加者年龄
大体时间:基线
|
基线
|
|
|
参与者性别
大体时间:基线
|
基线
|
|
|
一线治疗持续时间(从开始到停止治疗的时间)
大体时间:最长5年
|
最长5年
|
|
|
定义为每名参与者每8周接受的红细胞单位数
大体时间:长达5年
|
长达5年
|
|
|
达到血液学改善-红系(HI-E)的参与者数量
大体时间:最长5年
|
最长5年
|
|
|
实现红细胞(RBC)输血独立(TI)的参与者人数
大体时间:最长 5 年
|
最长 5 年
|
|
|
经历输血负担变化的参与者人数(每8周接受的红细胞单位数量变化)
大体时间:最多5年
|
最多5年
|
|
|
进展为高风险骨髓增生异常综合征 (MDS) 的参与者数量
大体时间:长达5年
|
长达5年
|
|
|
进展为急性髓系白血病(AML)的参与者人数
大体时间:最长5年
|
最长5年
|
|
|
对一线治疗无反应的参与者数量
大体时间:最长5年
|
最长5年
|
|
|
在初始血液学反应后经历反应丧失/继发性失败的患者数量
大体时间:最长5年
|
最长5年
|
|
|
死因
大体时间:最长5年
|
最长5年
|
|
|
严重不良事件(SAEs)
大体时间:长达5年
|
长达5年
|
|
|
一线治疗起始年份
大体时间:基线
|
基线
|
|
|
参与者身体质量指数 (BMI)
大体时间:基线
|
基线
|
|
|
参与者查尔森合并症指数(CCI)评分
大体时间:基线
|
基线
|
|
|
参与者查尔森合并症指数(CCI)个体合并症
大体时间:基线
|
基线
|
|
|
吸烟状况
大体时间:基线
|
基线
|
|
|
Proportion of participants receiving each first-line treatment category
大体时间:Up to 5-years
|
Treatment categories include:
|
Up to 5-years
|
|
Proportion of participants by treatment category at each line of therapy
大体时间:Up to 5-years
|
Treatment category received at each line of therapy (first line, second line, third line and beyond), categorized as erythropoiesis-stimulating agents (ESA), luspatercept, hypomethylating agents (HMA), lenalidomide, or conservative management (red blood cell transfusions without disease-modifying therapy). Treatment sequences will be derived from retrospective medical chart abstraction of documented treatment start and stop dates. |
Up to 5-years
|
|
Number and Rate of Healthcare Resource Utilization Events
大体时间:Up to 5-years
|
Healthcare resource utilization events, including primary care visits, specialist visits, outpatient visits all-cause hospitalizations, transfusion-related hospitalizations, general laboratory tests, number of prescriptions related to transfusion-dependent lower-risk myelodysplastic syndromes, red blood cell transfusions, use of concomitant medicines related to other comorbidities as documented in participant medical records. |
Up to 5-years
|
|
Number of serious cardiovascular events requiring emergency room visit or hospitalization
大体时间:Up to 5-years
|
Cardiovascular events include: will include acute myocardial infarction or acute coronary syndrome, heart failure decompensation, clinically significant arrhythmias (including atrial fibrillation/flutter and ventricular arrhythmia), stroke or transient ischemic attack, and venous thromboembolism. |
Up to 5-years
|
合作者和调查者
调查人员
- 研究主任:Bristol-Myers Squibb、Bristol-Myers Squibb
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.